the MDR gene as well as to determine the status of your bone marrow 
function after ABMT and chemotherapy. 
Chest X Rays and CT Scans will be required at regular intervals to 
assess the status of your cancer. These tests would be necessary 
regardless of the treatment you receive. 
The benefits to you of your participation in this study may not be 
immediately apparent or may not occur at all. If you do benefit it 
may be due to your ability to better tolerate various MDR 
responsive drugs after bone marrow transplantation should your 
cancer recur or be incompletely eradicated and if you and your 
physician decide on instituting further treatment. In addition, 
this study may provide us with insights into how to use the 
principle of gene therapy to attempt to help other patients with 
various tumors and genetic defects. In this way you would be aiding 
society by providing new scientific data. 
Should you decide not to participate in this study, it will not 
affect your treatment at CPMC including high dose chemotherapy and 
ABMT without gene therapy. However, there are no specific 
alternatives to the new approach being offered in this study other 
than nonparticipation in the study. 
The costs of extra blood and marrow tests required for this study 
will be covered by the study. In addition, any potential 
complications arising from the gene transduction process will also 
be covered by the study. You will still be responsible for paying 
for the transplant and all the regular visits and tests required to 
care for your cancer. We will attempt to expedite your visits to 
the physician so that you do not need to spend more time in the 
hospital than you normally would if you did not participate in this 
study. 
Any information obtained during this study and identified with you 
will be kept strictly confidential. All information accrued in this 
study will be released in the form of a number assigned to you to 
identify you to the investigators involved in the study. In any 
publications, only these numbers will used. There will be no need 
at any time during the course of this study for disclosure of your 
participation other than that associated with your informed 
consent . 
Your participation in this study is completely voluntary. You can 
withdraw from or refuse to participate in the study at any time 
without prejudicing your medical care at Columbia Presbyterian 
Medical Center. 
You will be given sufficient time to consider your participation in 
this study. Should you have any questions you can call Dr. 
Hesdorffer at 212-305-1738 and he will meet with you in order to 
answer any further questions you may have. If you have questions as 
to your rights as a research subject, you may call the 
Institutional Review Board at 212-305-6950. 
Recombinant DNA Research, Volume 18 
[ 121 ] 
